Congestive Heart Failure
SPORANOX® (itraconazole) Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of SPORANOX® Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Drug Interactions: Coadministration of cisapride, pimozide, quinidine, dofetilide, or levacetylmethadol (levomethadyl) with SPORANOX® (itraconazole) Capsules, Injection or Oral Solution is contraindicated SPORANOX®, a potent cytochrome P450 3A4 isoenzyme system (CYP3A4) inhibitor, may increase plasma concentrations of drugs metabolized by this pathway. Serious cardiovascular events, including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or sudden death have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), or quinidine, concomitantly with SPORANOX® and/or other CYP3A4 inhibitors. See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions for more information.
SPORANOX® is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers.
SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in
immunocompromised and non-immunocompromised
Blastomycosis, pulmonary and extrapulmonary
Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and
Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.
Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly.
SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in
Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and
Onychomycosis of the fingernail due to dermatophytes (tinea unguium).
Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis.
(See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Published Studies Related to Sporanox (Itraconazole)
Itraconazole vs. trimethoprim-sulfamethoxazole: A comparative cohort study of 200
patients with paracoccidioidomycosis. 
Paracoccidioidomycosis (PCM) is a systemic mycosis endemic to Latin America. Brazil accounts for approximately 80% of cases, where it represents a major
public health issue due to its disabling impact and the number of premature
deaths it causes... Although the results of this study show that
itraconazole was the best treatment option for PCM patients, a double-blind,
randomized, controlled trial is necessary to confirm this conclusion.
Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. [2011.08]
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks...
Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. [2011.05]
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. OBJECTIVE: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis... CONCLUSION: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. [2011.04]
OBJECTIVE: To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers... CONCLUSION: Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered. Copyright (c) 2011 John Wiley & Sons, Ltd.
Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. [2011.03]
PURPOSE: The risk of invasive fungal infection is greater for allogeneic hematopoietic stem cell transplantation (HSCT) than for autologous transplantation. Therefore, many transplantation centers use antifungal prophylaxis for allogeneic HSCT, however, there exists no standard guidelines or consensus regarding autologous HSCT... CONCLUSION: Although beneficial effects such as a shorter duration of fever and reduced need for antibiotic use were observed in the prophylaxis group, the results were not sufficient to draw a definite recommendation about the routine use of antifungal prophylaxis in pediatric autologous HSCT recipients with high-risk solid tumors (Trial registration: NCT00336531).
Clinical Trials Related to Sporanox (Itraconazole)
A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer [Recruiting]
To evaluate the 3-month event-free survival of the combination of the combination of
itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung
To determine the objective response rate of the combination of itraconazole and pemetrexed
in patients with recurrent/refractory non-small cell lung cancer.
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. [Active, not recruiting]
Onychomycosis is a common condition accounting for approximately half of all nail disorders.
It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment
of onychomycosis in the United States with an approved dosage regimen for the treatment of
onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two
100mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200mg tablet which could
be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will
compare the efficacy and safety of this new tablet formulation with itraconazole capsules and
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy [Recruiting]
This research is being done to test an investigational drug, called itraconazole, in the
treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration
(FDA) for the treatment of various fungal infections such as fingernail/toenail infections
and other more serious fungal infections. The word "investigational" means that itraconazole
is not approved for use in people with cancer. However, the FDA is allowing the use of
itraconazole in this research study. Itraconazole has been shown to have activity against
cancer (including prostate cancer) in the laboratory, but has not been tested against cancer
The purpose of this study is to find out:
- If itraconazole is safe when given at two different doses
- How itraconazole affects prostate specific antigen (PSA): a blood test that measures
substances released by prostate cancer
- Whether itraconazole can delay further prostate cancer growth and spread
- How itraconazole affects other markers of prostate cancer
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas [Recruiting]
BCCs are the most common human cancer in the US and affect over 1 million people. There is
no effective drug to prevent basal cell carcinomas of the skin. We hope to learn if an oral
antifungal drug, Itraconazole, might inhibit a marker of proliferation and a biomarker
(tumor signaling pathway) of BCC development. Itraconazole is an FDA-approved drug for the
treatment of fungal infections of the skin, and has been used for the past 25 years with
relatively few side effects. It has been shown in mice to reduce a BCC biomarker and to
reduce growth of BCCs. Thus, it could potentially reduce BCC growth in humans.
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection [Recruiting]
Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients
receiving chemotherapy for leukemia, or submitted to stem cell transplantation. Patients
with a history of invasive fungal infection (IFI) are at high risk of developing relapse and
Prompt intensive antifungal therapy, have improved responses and survival, allowing an
increase of antifungal treatments, including secondary antifungal prophylaxis.
Few studies have addressed the role of previous IFI in the feasibility of stem cell
transplant, or the secondary prophylaxis with antifungal drugs in preventing recurrence of
infection after transplantation. However, given the lack of prospective studies, the role of
secondary antifungal prophylaxis remains unclear.
Itraconazole is a wide-spectrum triazole antifungal agent active against Candida albicans,
non-albicans, Aspergillus spp., Blastomyces dermatitidis, Blastomyces coccidioides,
Cryptococcus neoformans, Sporothrix schenkii, Paracoccidioides brasiliensis, Histoplasma
spp. and various kinds of yeast fungi and mycetes.
The role of itraconazole IFI prophylaxis treatment has been proved by many interventional
studies. In this prospective, multicentric study of secondary prophylaxis, itraconazole will
be given at standard dose to patients undergoing allogeneic stem cell transplantation or
chemotherapy with prior invasive fungal infection, to assess the efficacy and safety of
itraconazole secondary prophylaxis.
Reports of Suspected Sporanox (Itraconazole) Side Effects
Oedema Peripheral (7),
Drug Ineffective (5),
Cardiac Failure Congestive (5),
Self Injurious Behaviour (5),
Diabetes Mellitus (4),
Erectile Dysfunction (4), more >>
Page last updated: 2014-11-30